The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Haitian Acquires Hong Kong’s Amoy Food to Add an Established Overseas Platform

Foshan Haitian Flavouring and Food（海天味业）has completed the acquisition of all equity interests in Amoy Food Limited（淘大）, the Hong Kong food brand founded in 1908. The deal gives China’s leading condiment producer an established international brand and sales network, rather than requiring it to build overseas distribution market by market.

Unpacking China | Key Chinese Firms to Watch This Week （06/09/2026-12/09/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

DYU Raises Nearly CNY 100 Million in Pre-B Round to Expand Overseas Retail and Smart-Mobility Products

DYU（大鱼智行）, a Chinese electric-bike and smart light-mobility company, announced on September 10 that it had completed a Pre-B funding round of nearly CNY 100 million. Tongxin Capital（同鑫资本）led the round, with several other institutional investors participating. The proceeds will support product development, AI capabilities, international brand building and supply-chain improvements.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.